Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H), a Canadian oncology company focused on cancer research and treatment, is advancing its preclinical candidate ONC010 toward clinical development. ONC010 is a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms that enable cancer survival and treatment resistance. The company has completed a 300-gram API scale-up with approximately 99.3% purity, expanded manufacturing capabilities through a partnership with Nanosoft Polymers, and is progressing metabolism, analytical, licensing, and other IND-enabling activities.
These developments are detailed in a recent announcement disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H). The ability to produce high-purity API at scale is a critical step for any drug candidate moving toward human trials, as it demonstrates that manufacturing can meet the rigorous demands of clinical and eventual commercial supply. The partnership with Nanosoft Polymers further strengthens the company’s manufacturing infrastructure.
Onco-Innovations has also arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches, to support ONC010 development, the SynoGraph platform, and general corporate needs. The company notes that the eventual proceeds may differ from the stated notional amount. This financing provides a steady runway for the company’s research and development efforts. Additionally, the appointment of Dave Antony as CFO adds financial and corporate experience as the company continues IND-enabling work.
The company is targeting a planned Phase 1 study of ONC010 in Australia. This would represent a major milestone, transitioning ONC010 from preclinical research into human testing. The study would assess the safety and tolerability of the candidate, a necessary step before larger efficacy trials. Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumours, positioning it in a high-demand area of oncology.
For investors, these advancements signal progress in the company’s pipeline. The completion of API scale-up and the financing arrangement suggest that Onco-Innovations is building the necessary foundation for clinical development. The company’s newsroom is available at https://nnw.fm/ONNVF, where updates relating to ONNVF can be found. A full article on this development is available at https://nnw.fm/YPLe7.
The announcement was distributed via NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. NetworkNewsWire provides access to wire solutions through InvestorWire and offers editorial syndication to 5,000+ outlets, among other services. For more details on the company, visit its website at https://oncoinnovations.com/.
